Advise females of reproductive potential to use effective contraception during therapy with Femara and for at least 3 weeks after the last dose [see ADVERSE REACTIONS , Use In Specific Populations and CLINICAL PHARMACOLOGY]. Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertility A ...
Advise females of reproductive potential to use effective contraception during treatment and for at least 3 weeks after last dose Infertility Therapy may impair fertility in females and males of reproductive potential Lactation Not known if therapy is present in human milk; there are no data on effe...
Advise females of reproductive potential to use effective contraception during treatment with Femara and for at least 3 weeks after the last dose. Infertility Females Based on studies in female animals, Femara may impair fertility in females of reproductive potential [see Nonclinical Toxicology (...
The usual dose of Femara is 2.5 mg and takes one tablet a day. It is to be taken for 5 days per month from day 2 to day 6 of the menstrual cycle. Day one is the first day of the period. It is worth noting that doctors might give different treatment plans and it is important t...
the drugs in Kisqali Femara Co-Pack pass into breast milk. Because of the potential for serious adverse reactions in breastfed infants from Kisqali Femara Co-Pack, lactating women are advised not to breastfeed while taking Kisqali Femara Co-Pack and for at least 3 weeks after the last dose....